Nanosuspensions for intravenous administration
AssigneeNovartis AG
InventorsHans Georg Weder, Peter van Hoogevest
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition for the intravenous administration of the sparingly soluble staurosporin derivative N-benzoyl-staurosporin. The composition comprises the following preferred components: a) the therpeutic agent N-benzoyl-staurosporin; b) a polyoxyethylene/polyoxypropylene block copolymer; c) ethanol and water as carrier liquids; and d) purified lecithin from soybeans and e) as water-soluble excipients glycerol and sorbitol.
Claims11
A pharmaceutical composition for the intravenous administration of a staurosporin derivative comprising
- a) a staurosporin derivative which is sparingly soluble in water;
- b) a polyoxyethylene/polyoxypropylene block copolymer;
- c) ethanol and water as carrier liquids in the degree of purity prescribed for intravenous administration;
- and optionally
- d) a phospholipid of the formula ##STR4## wherein R.sub.1 is C.sub.10-20 acyl;
- R.sub.2 is hydrogen or C.sub.10-20 acyl;
- R.sub.3 is hydrogen, 2-trimethylamino-1-ethyl, 2-amino-1-ethyl, C.sub.1-4 alkyl, C.sub.1-5 alkyl substituted by carboxy, C.sub.2-5 alkyl substituted by hydroxy, C.sub.2-5 alkyl substituted by carboxy and hydroxy, C.sub.2-5 alkyl substituted by carboxy and amino, or an inositol or a glyceryl group, or a salt of such a compound;
- and/or
- e) water-soluble excipients suitable for injections.
A method of treating a tumor comprising administering a therapeutically effective amount of a nanosuspension comprising N-benzoyl-staurosporin to a patient in need thereof.
Dependencies are inferred from the claim text.